The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

Annals of Oncology

Volumn 28, Issue 2, 2017, Pages 321-328

  Pruneri, G ^a,b   Lazzeroni, Matteo ^a   Bagnardi, V ^a,c   Tiburzio, G B ^a   Rotmensz, N ^a   DeCensi, A ^a,d   Guerrieri Gonzaga, A ^a   Vingiani, A ^a   Curigliano, G ^a   Zurrida, S ^a   Bassi, F ^a   Salgado, R ^e   Van den Eynden, G ^e   Loi, S ^f   Denkert, C ^g,h   Bonanni, B ^a   Viale, G ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e JULES BORDET INSTITUTE   (Belgium)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h German Cancer Consortium (DKTK)   (Germany)

Author keywords

Ductal carcinoma in situ; Tumor infiltrating lymphocytes

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RETINOID DERIVATIVE; RETINOID FENRETINIDE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST SURGERY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER SURGERY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR NECROSIS; BREAST TUMOR; IMMUNOLOGY; PATHOLOGY; PREVENTION AND CONTROL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 85014280869     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw623     Document Type: Article

References (21)

1. Correa C, McGale P, Taylor C et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010; 2010: 162-177.
2. Cuzick J, Sestak I, Pinder SE et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011; 12: 21-29.
3. Rudloff U, Jacks LM, Goldberg JI et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010; 28: 3762-3769.
4. Solin LJ, Gray R, Baehner FL et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013; 105: 701-710.
5. Lazzeroni M, Guerrieri-Gonzaga A, Botteri E et al. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer 2013; 108: 1593-1601.
6. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
7. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966.
8. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat 2014; 148: 467-476.
9. Salgado R, Denkert C, Demaria S et al. The evaluation of tumorinfiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
10. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
11. Harrell FE, Jr, Lee KLMark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med 1996; 15: 361-387.
12. Polley MY, Leung SC, McShane LM et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-1906.
13. Curigliano G, Disalvatore D, Esposito A et al. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol 2015; 26: 682-687.
14. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550.
15. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67: 1842-1852.
16. Chapman C, Murray A, Chakrabarti J et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868-873.
17. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-5380.
18. Lal A, Chan L, Devries S et al. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 2013; 139: 381-390.
19. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27: 16-25.
20. Liu S, Lachapelle J, Leung S et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14: R48.
21. Eiro N, Pidal I, Fernandez-Garcia B et al. Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One 2012; 7: e52796.